Viewing Study NCT01143233


Ignite Creation Date: 2025-12-25 @ 3:01 AM
Ignite Modification Date: 2025-12-26 @ 1:41 AM
Study NCT ID: NCT01143233
Status: COMPLETED
Last Update Posted: 2017-11-30
First Post: 2010-06-11
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Low-protein Infant Formula With Partial or Extensive Proteinhydrolysate 4 Year Follow-up
Sponsor: HiPP GmbH & Co. Vertrieb KG
Organization:

Study Overview

Official Title: Suitability of an Infant Formula With Reduced Protein Content Based on a Partial Respectively an Extensive Proteinhydrolysate With and Without Pro- and Prebiotics for the Particular Nutritional Use by Infants.-Extension by 4 Year Follow-up
Status: COMPLETED
Status Verified Date: 2017-11
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: HippHA
Brief Summary: The study is conducted to examine the suitability of partially respectively extensively hydrolyzed low protein infant formulae with and without pro- and prebiotics for healthy, term infants.

Primary hypothesis to be tested is: an infant formula based on a Protein hydrolysate with modified protein content is non inferior compared to a standard infant formula based on a Protein hyrolysate in respect to proper growth of healthy, term infants within the first four month of life.

4-year follow-up (without further Intervention) will focus on body composition and allergic predisposition.
Detailed Description: View Section Brief Summary

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: